| abstract |
1.- A method to improve a multiple sclerosis symptom in a subject, the method comprises: Administering to the subject an agonist of an interleukin-21 (IL-21) / IL-21 (IL-21R) receptor in a sufficient amount to improve in multiple sclerosis symptoms, wherein said agonist is selected from the group consisting of an IL-21 polypeptide, an agonistic anti-IL-21 R antibody and an antigen-binding fragment of an anti-IL-21 R antibody agonistic. 2. The method of claim 1, wherein the agonist is an IL-21 polypeptide comprising a sequence of at least 90% identical to the amino acid sequence of Sec. ID No .: 2 and is capable of binding to an IL-21 R.3.- The method of claim 1, wherein the agonist is an IL-21 polypeptide comprising a sequence of at least 95% identical to the amino acid sequence of the ID of Sec. No .: 2 and is capable of binding an IL-21 R.4.- The method of claim 1, wherein the agonist e s an IL-21 polypeptide comprising an amino acid sequence of Seq. ID No .: 2.5.- The method of claim 1, wherein the agonist is an agonistic anti-IL-21 R antibody or a fragment that binds to the antigen thereof. 6. The method of claim 5, wherein the agonistic anti-IL-21R antibody is a human antibody. 7. The method of claim 1, further comprising administering to the subject at least an anti-inflammatory agent. 8. The method of claim 7, wherein the anti-inflammatory agent is selected from the group consisting of IFN ß-Ia, IFNß -1ß, TNF agonist, IL-12 agonist, IL-agonist 23, methotrexate, leflunomide, sirolimus (rapamycin), and CCI-779. |